Heart failure (HF) still has a discouraging prognosis. Therapeutic strategies aim to reduce
mortality as well as slow the progression of the disease, improve symptoms and reduce the …

OBJECTIVE: To evaluate the evidence for valsartan in the treatment of heart failure and
determine its need for formulary inclusion. DATA SOURCES: OVID and PubMed databases …

Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Objective: To evaluate the effect on cardiac hemodynamic parameters of valsartan in
patients with chronic stable congestive heart failure previously untreated with ACE inhibitors …

Aims To investigate the effect of valsartan in the Valsartan‐Heart Failure Trial (Val‐HeFT)
when added to angiotensin‐converting enzyme inhibitor (ACEi) alone in patients with heart …

Abstract▲ Valsartan, an orally active nonpeptide angiotensin II (AII) receptor antagonist with
selectivity for the AII type I (AT 1) receptor subtype, has recently been approved by the US …

Abstract Background The Valsartan Heart Failure Trial (Val‐HeFT) is the first large‐scale
randomized, multinational clinical study to assess the efficacy and safety of valsartan, an …

Angiotensin II receptor blockers (ARBs) are the most recent class of anti‐hypertensive drug
to enter clinical use for chronic heart failure (CHF). In the landmark Valsartan Heart Failure …

Although a cornerstone in the treatment of heart failure, angiotensin-converting enzyme
inhibitors are under-used, partly due to side effects. If proven at least similarly efficacious to …

The aims of the treatment of heart failure are to improve the quality of life and slow the
progression of cardiac disease. Improvement of quality of life is best assessed by …